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Abstract: In a brain-targeting prodrug approach for a metabolically stable enkephalin analogue DADLE, specific en-
zymes are utilized for in vivo prodrug activation. Prolyl oligopeptidase (POP) may be especially useful in this regard. In 
vitro metabolic stability of the putative metabolites of prodrugs having various “spacers” has shown that POP provides 
significantly faster release of DADLE from conjugates having dipeptidyl spacer (specifically Xaa-Pro or Xaa-Ala) than 
alternative peptidases utilized when single amino acids are used as spacers. In vitro half-lives measured in rat brain ho-
mogenate showed excellent correlation with CNS-mediated analgesia using the tail-flick model in rats providing, thus, an 
in vivo substantiation of the prodrug approach relying on POP as the peptidase to release DADLE. 
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INTRODUCTION 
  Enkephalins are opioids and potential neuropharmaceuti-
cals for pain relief without the undesired side-effects associ-
ated with the use of morphine and other alkaloid analgesics 
[1]. These endogenous linear pentapeptides are, however, 
easily degraded by peptidolytic enzymes [2] rendering their 
action short-lasting, unless peptidase inhibitors are used si-
multaneously [3]. Therefore, a wide variety of analogues 
with increased in vivo stability have been designed and 
evaluated. A -opioid receptor-selective enkephalin analogue 
Tyr-D-Ala-Gly-Phe-D-Leu (DADLE), is a representative of 
such compounds [4]. In spite of adequate metabolic stability 
of DADLE and the majority of synthetic neuropeptide ana-
logues, these agents still face a formidable obstacle, the 
blood brain barrier (BBB), in terms of reaching the central 
nervous system (CNS) upon systemic administration [5]. The 
BBB, acting as a lipoidal bilayer, practically excludes the 
entry of these hydrophilic substances into the brain by pas-
sive transport. Additionally, BBB may also represent an en-
zymatic barrier for peptides. As such, the limited bioavail-
ability of the otherwise promising peptide-based neurophar-
maceuticals presents a major disadvantage for practical drug 
development. 
  Invasive and non-invasive strategies have been devel-
oped to outwit the BBB [6]. Among non-invasive methods, 
prodrug design is perhaps the most versatile chemical ma-
nipulation technique that bioreversibly modifies the parent   
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peptide for improving CNS bioavailability and targeting. A 
specific approach within prodrug design is the use of a brain-
targeting chemical delivery system (BTCDS) [7]. BTCDS, 
as a prodrug, is biologically inactive per se [8] and requires 
in vivo enzymatic conversion(s) to the biologically active 
agent and provides enhanced drug delivery to the brain, the 
site of action. In peptide-based BTCDS, the lipophilic 1,4-
dihydrotrigonellyl transport moiety [7] is covalently attached 
to the N-terminus of the parent peptide via “spacer” amino 
acid(s). In the brain, however, a coenzyme associated with 
numerous oxidoreductases and cellular respiration oxidizes 
the dihydropyridine to permanently charged N-methylpyridi-
nium (trigonellyl, T
+), analogously to the oxidation of NAD 
(P)H to NADP
+ [7]. The “oxidized” BTCDS apparently can-
not leave the brain by passive transport, and it has not been 
identified as a potential substrate for endogenous efflux 
transporters either [9]. A strategically selected spacer en-
sures, then, the release of the parent peptide in the brain by 
specific peptidases [10, 11] that remove the T
+-Spacer moi-
ety [11] from the “oxidized” BTCDS. 
  Previously, we have reported a successful application of 
this approach to transport DADLE [11, 12] into the brain 
(Fig.  1). The C-terminus of DADLE was esterified with 
highly lipophilic alcohols, such as cholesterol (Ch-OH) to 
furnish adequate lipophilicity of the BTCDS necessary to 
BBB transport [9]. This ester group can easily be cleaved by 
lipases and/or esterases during or after diffusion through the 
BBB. Alanine (Ala) or proline (Pro)-based spacer (S) was 
originally chosen because of the suggested involvement of 
alanyl and prolyl aminodipeptidyl peptidases (EC 3.4.14.2 
and/or EC 3.4.14.5) [13] in the enkephalinergic transmission 
in the brain. However, as it turned out [14], these enzymes 
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such as thyrotropin releasing hormone, from the correspond-
ing “oxidized” BTCDS. Additionally, peptidyl glycine -
amidating monooxygenase (PAM) may also be exploited for 
peptide-based brain-targeting prodrug design [14,15]. 
 In  vivo substantiation of the approach for DADLE shown 
in Fig. (1) was done by monitoring the antinociceptive effect 
produced after intravenous (iv) administration of BTCDSs in 
rats. Although BTCDSs containing either Pro or Ala spacer 
(1a and 1b, respectively) showed a profound, centrally-
mediated and long-lasting analgesia, 1a was more potent 
than 1b  in terms of producing a quicker onset and longer 
duration of tail-flick latencies [12]. Consequently, we con-
cluded that the “spacer” was the most important architectural 
element of the BTCDS (1a-d) to manipulate the rate of 
DADLE release and, thus, the production of analgesia by 
utilizing specific peptidases (probably EC 3.4.14.2 and/or 
EC 3.4.14.5). We have also reasoned that another type of 
enzymes such as prolyl oligopeptidase (POP, EC 3.4.21.26, 
that has specific cleaving sites in a peptide sequence [16] 
may also be used to control peptide release from the oxidized 
BTCDSs according to the therapeutic objectives. 
  The present studies were undertaken to provide in vitro 
evidence of this hypothesis [17], together with an in vivo 
investigation of the pharmacological consequences of intro-
ducing Pro-Pro (1c) and Ala-Ala (1d) dipeptidyl spacers into 
BTCDSs for potential exploitation of POP [16] in brain-
targeting delivery of DADLE by prodrug design. 
SYNTHESIS 
  Selected BTCDSs having Pro-Pro or Ala-Ala spacer and 
Cho ester on their C-termini (1c and 1d, Fig. 1) were synthe-
sized analogously to that of 1a and 1b (S=Pro and S=Ala, 
respectively) by a segment coupling method we have devel-
oped to obtain these types of peptide conjugates [12]. 
Briefly, Nicotinoyl-(S)-D-Ala-Gly-Phe-OH was prepared by 
routine Fmoc-based solid phase peptide synthesis (SPPS) in 
a Synthor 2000 instrument (Peptide International, Louisville, 
KY) and then coupled to D-Leu-OCho in solution phase us-
ing PyBOP/HOBt/DIPEA activation The latter lipophilic 
ester of the C-terminal amino acid (D-Leu-OH) was prepared 
by solution-phase Boc-chemistry. Once Nicotinoyl-(S)-
DADLE-OCho was assembled, column chromatographic 
purification (silicagel, chloroform/methanol 9:1, v/v) was 
done. Then the nicotinoyl residue was converted to trigonel-
lyl (T
+) using MeI. After the well-established reduction using 
Na2S2O4  [18] the BTCDSs were obtained. This reduction 
was conveniently monitored by UV spectroscopy (Lambda 
11 UV/Vis Perkin Elmer spectrometer; Perkin Elmer Anal. 
Inst., Norwalk, CT) in methanol that showed the unequivocal 
conversion of T
+ ( =254 nm) to 1,4-dihydropyridine (T) 
(=355 nm). The putative oxidized metabolites 2a-e from 
which DADLE may be directly released were also synthe-
sized by routine Fmoc-based SPPS. As control, 2g having no 
spacer moiety was also prepared. All test compounds were 
thoroughly purified by reversed-phased high performance 
liquid chromatography (RP-HPLC) and identified by elec-
trospray-ionization mass spectrometry (ESI-MS), as de-
scribed before [12]. 
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Fig. (1). Schematic illustration of a BTCDS for DADLE, Tyr-D-
Ala-Gly-Phe-D-Leu. OCho represents cholesteryl ester [12]. 
IN VITRO STABILITY STUDIES 
  Stability studies of the predicted biotransformation prod-
ucts, T
+-S-DADLE, of the BTCDSs have been performed in 
rat brain homogenate [17]. Approximately 250 nmol of 2a-g, 
dissolved in 100 mL DMSO, was added to 1 mL of freshly 
made rat brain homogenate (20% w/w, pH 7.4 Tris buffer 
[19]). For comparison, T
+-DADLE (2g), in which DADLE is 
directly attached to T
+ was also studied to underline the im-
portance of the “spacer” in the molecular architecture of such 
type of BTCDSs. The mixture was incubated at 37 °C in a 
temperature controlled, shaking water bath. Aliquots (100 
L) were taken after 5, 15, 30, 45, 60, and 90 min of incuba-
tion, and transferred to 1.5 mL plastic centrifuge tubes con-
taining 200 L of ice-cold 1 M aqueous acetic acid. After 
centrifugation at 12500g for 15 min, the supernatant was 
removed and analyzed by microbore HPLC on a system con-
sisting of a ThermoSeparation/Spectra-Physics (Fremont, 
CA) Spectra Series P200 binary gradient solvent delivery 
system, a Rheodyne (Cotati, CA) Model 7125 injector valve 
equipped with a 5 L sample loop, a Spectroflow 757 vari-
able wavelength UV/Vis detector (Kratos Analytical, Man-
chester, U.K.) operated at 216 nm. 
  As shown in Table 1, the conjugate without a spacer (2g) 
is extremely stable (t is almost 8 h); thus, no release of 
DADLE in the brain could be expected from the correspond-
ing prodrug. This finding supports the notion that amidase 
activity is low in the brain [7]. When a single amino-acid 
spacer was used and prolyl and alanyl aminodipeptidyl pep-
tidases were the apparent processing enzymes responsible 
for DADLE release, 2a (S=Pro) was approximately 3-times 
less stable than 2b (S=Ala). This observation is in agreement 
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earlier onset of analgesia was produced with Pro (1a) com-
pared to that of Ala (1b) as a spacer (see Table 3). 
  When dipeptidyl spacers (specifically Xaa-Pro or Xaa-
Ala) were used where POP is expected to be the processing 
enzyme [16], then the half-life of 2c (S =Pro-Pro) was espe-
cially short (<10 min), suggesting the very quick release of 
DADLE in the brain. Interestingly, in case of Ala-Ala (2d), 
Pro-Ala (2e) or Ala-Pro (2f) combinations, the in vitro half-
lives were practically the same (around 20 min) that may 
imply that the affinity of POP to Pro is somewhat higher 
than to Ala, especially when Pro is the preceding amino acid. 
(Under our experimental conditions, t1/2 for DADLE was 
around 730 min). Nevertheless, these in vivo data clearly 
show that the metabolic stability and, thus, DADLE–
releasing rate of the putative metabolites (2a-f) of the corre-
sponding BTCDSs can be manipulated by strategically se-
lecting the spacer function. 
Table 1.  Metabolic Stability of T
+-S-DADLE and T
+-DADLE 
in Rat Brain Homogenate 
 
Putative Metabolite  t1/2 (min) 
T
+-Pro-DADLE (2a)   346 
T
+-Ala-DADLE (2b)   963 
T
+-Pro-Pro-DADLE (2c)   9 
T
+-Ala-Ala-DADLE (2d)   23 
T
+-Pro-Ala-DADLE (2e)   24 
T
+-Ala-Pro-DADLE (2f)   24 
T
+-DADLE (2g)   4620 
Concentration–time profiles were analyzed by exponential fitting assuming pseudo-
first order degradation. In vitro half-lives (t1/2) were calculated from rate constant (k) as 
0.693/k. 
 
Table  2.  Metabolic Stability of T
+-Pro-Pro-DADLE (2c) in 
Homogenates of Rat Brain Sections 
 
Brain Section  t1/2 (min) 
Cortex 4 
Medulla Oblongata  72 
Cerebellum 9 
Striatum 12 
Hypothalamus 28 
Mid-brain 12 
Whole brain  9 
Concentration-time profiles were analyzed by exponential fitting assuming pseudo-first 
order degradation. In vitro half-lives (t1/2) were calculated from rate constant (k) as 
0.693/k. 
 
 The  in vitro release of DADLE and the concomitant loss 
of the T
+-S moiety were unequivocally shown by ESI-MS 
analysis (data not shown) [12,17]. Altogether, it can be con-
cluded that POP, indeed, can be utilized for the release of 
DADLE from the corresponding oxidized BTCDSs. The   
 
measured very short in vitro half-lives in brain homogenate 
may also predict a quick onset of analgesia upon i.v. admini-
stration of the BTCDSs having dipeptidyl spacers. 
  The distribution of POP activity within the brain was also 
investigated by incubating 100 M  2c (S=Pro-Pro) in ho-
mogenates of different brain sections (Table 2) analogously 
to the metabolic studies involving whole brain homogenate 
(Table 1). Among the studied brain sections, the highest me-
tabolism was measured in the cortex, while 2c was quite 
stable (t1/2 > 1 h) in the medulla oblongata indicating low 
POP activity in this region of the brain. These observations 
are in agreement with findings about the uneven distribution 
of POP in the brain [20, 21]. Therefore, because POP is ex-
clusively expressed by neurons and display region-specific 
distribution in the mouse brain, POP-activated prodrugs may 
be especially useful to target neurons in select regions (cor-
tex, cerebellum, striatum and mid-brain) of the brain. 
ANALGESIC ACTIVITY 
 In  vivo substantiation of the in vitro metabolic stability 
studies (Table 1) and, thus, DADLE release in the brain from 
1c and 1d as representative prodrugs having dipeptidyl 
spacer was done by monitoring CNS-mediated analgesia in 
rats upon i.v. injection of the BTCDSs (in 1:9 v/v DMSO : 
20% w/v aqueous hydroxypropyl--cyclodextrin) using the 
tail-flick model [11, 12, 22]. The latency of the tail-flick 
response to radiant heat (focused in the middle of the tail) 
was measured by using a Tail-Flick Analgesia Meter 0570-
001L (Columbus Instruments, Columbus, OH, USA). Base-
line latencies (5-6 s) were collected for 15 min prior to pro-
drug administration, and tail-flick latency was measured at 
various times up to 6 h following BTCDS administration. 
Groups of 5-10 animals were treated with vehicle control or 
the prodrugs at 4.2 mol/kg of body weight dose. Data gen-
erated from the studies comparing treatment groups were 
subjected to analysis of variance (ANOVA) followed by 
Dunnett’s post hoc procedure to detect significant differ-
ences (P> 0.05) between groups [23]. 
  Administration of the dipeptidyl spacer-containing pro-
drugs (1c and 1d) produced analgesia significantly faster 
than prodrugs having single amino acid spacer (1a and 1b, 
respectively) as shown in Table 3. These data show excellent 
correlations with the measured in vitro half-lives (Table 1). 
The corresponding putative metabolites 2c and 2d were ap-
proximately 40-fold less stable in vitro than 2a and 2b,  
respectively, although more potent antinociception was ob-
served with the use of single amino acid spacers where 
dipeptidyl aminopeptidase was the processing enzyme. 
  In summary, our data clearly show that utilizing POP in 
brain-targeting prodrug design to transport peptides into the 
brain could be especially useful when the therapeutic objec-
tive calls for a very quick onset of action, thus, release of the 
parent peptide. We have also envisioned that, by optimizing 
the amino acid that precedes Pro or Ala in the dipeptidyl 
spacers shown here, the release of the biologically active 
peptide could further be controlled. These studies will be 
published separately. 
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Table  3.  Antinociception in Sprague-Dawley Rats After i.v. 
Injection (4.2 mol/kg Body Weight Dose) of Pro-
drugs 1a-d of DADLE 
 
Prodrug ~TMAX (min) Anti-Nociception
a 
1a 
S=Pro 
30 2.7 
1b 
S=Ala 
60 2.1 
1c 
S=Pro-Pro 
5 1.6 
1d 
S=Ala-Ala 
5-10 
 
1.8 
aAntinociception was defined as (Maximum latency –Baseline latency)/Baseline la-
tency. TMAX was defined as time (min) to reach maximum tail-flick latency. 
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